Head and Neck Cancer

Low-Dose Gemcitabine Sensitizes Cells to Radiation Treatment

Published in Cancer Weekly, April 3rd, 2001

by N.R. Saltmarsh, staff medical writer - Low doses of gemcitabine lessen the danger of toxicity and adequately sensitize tumor cells to radiation in patients with head and neck cancer, researchers have found.

A. Eisbruch and colleagues examined the efficacy of gemcitabine at various doses, weighed against its dose-limiting toxicity in a Phase I trial. They measured levels of gemcitabine triphosphate (dFdCTP) in biopsied tumor cells before and during a standard seven-week course of radiation treatment for locally advanced head and neck cancer.

Gemcitabine was given weekly in doses starting at 300 mg/m²/week, and tapering off to 150...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-04-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry